Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression

Science Translational Medicine

Volumn 8, Issue 356, 2016, Pages

  Hundhausen, Christian ^a   Roth, Alena ^a,b   Whalen, Elizabeth ^a   Chen, Janice ^a   Schneider, Anya ^a,c   Long, S Alice ^a   Wei, Shan ^a   Rawlings, Rebecca ^a   Kinsman, MacKenzie ^a   Evanko, Stephen P ^a   Wight, Thomas N ^a   Greenbaum, Carla J ^a   Cerosaletti, Karen ^a   Buckner, Jane H ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c KLINIKUM AUGSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR7; INTERLEUKIN 10; INTERLEUKIN 27; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; L SELECTIN; STAT1 PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; IL6 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE MIGRATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSCRIPTOMICS; AUTOIMMUNITY; CASE CONTROL STUDY; CELL MOTION; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; IN VITRO STUDY; METABOLISM; MIDDLE AGED; TRANSLATIONAL RESEARCH; YOUNG ADULT;

ADULT; AUTOIMMUNITY; CASE-CONTROL STUDIES; CELL MOVEMENT; DIABETES MELLITUS, TYPE 1; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IN VITRO TECHNIQUES; INTERLEUKIN-6; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TRANSLATIONAL MEDICAL RESEARCH; YOUNG ADULT;

EID: 84988888015     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad9943     Document Type: Article

References (60)

1. L. H. Calabrese, S. Rose-John, IL-6 biology: Implications for clinical targeting in rheumatic disease. Nat. Rev. Rheumatol. 10, 720-727 (2014).
2. T. Hirano, T. Matsuda, M. Turner, N. Miyasaka, G. Buchan, B. Tang, K. Sato, M. Shimizu, R. Maini, M. Feldmann, Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur. J. Immunol. 18, 1797-1801 (1988).
3. M. Linker-Israeli, R. J. Deans, D. J. Wallace, J. Prehn, T. Ozeri-Chen, J. R. Klinenberg, Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol. 147, 117-123 (1991).
4. D. Maimone, G. C. Guazzi, P. Annunziata, IL-6 detection in multiple sclerosis brain. J. Neurol. Sci. 146, 59-65 (1997).
5. E. B. Samoilova, J. L. Horton, B. Hilliard, T.-S. Liu, Y. Chen, IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: Roles of IL-6 in the activation and differentiation of autoreactive T cells. J. Immunol. 161, 6480-6486 (1998).
6. M. Fujimoto, S. Serada, M. Mihara, Y. Uchiyama, H. Yoshida, N. Koike, Y. Ohsugi, T. Nishikawa, B. Ripley, A. Kimura, T. Kishimoto, T. Naka, Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 58, 3710-3719 (2008).
7. T. Tanaka, M. Narazaki, T. Kishimoto, Therapeutic targeting of the interleukin-6 receptor. Annu. Rev. Pharmacol. Toxicol. 52, 199-219 (2012).
8. P. C. Heinrich, I. Behrmann, S. Haan, H. M. Hermanns, G. Müller-Newen, F. Schaper, Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374, 1-20 (2003).
9. S. Rose-John, P. C. Heinrich, Soluble receptors for cytokines and growth factors: Generation and biological function. Biochem. J. 300, 281-290 (1994).
10. J. Scheller, A. Chalaris, C. Garbers, S. Rose-John, ADAM17: A molecular switch to control inflammation and tissue regeneration. Trends Immunol. 32, 380-387 (2011).
11. V. Matthews, B. Schuster, S. Schütze, I. Bussmeyer, A. Ludwig, C. Hundhausen, T. Sadowski, P. Saftig, D. Hartmann, K. J. Kallen, S. Rose-John, Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J. Biol. Chem. 278, 38829-38839 (2003).
12. K. Althoff, P. Reddy, N. Voltz, S. Rose-John, J. Müllberg, Shedding of interleukin-6 receptor and tumor necrosis factor a. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur. J. Biochem. 267, 2624-2631 (2000).
13. E. Bettelli, Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, V. K. Kuchroo, Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
14. M. Veldhoen, R. J. Hocking, C. J. Atkins, R. M. Locksley, B. Stockinger, TGFb in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179-189 (2006).
15. W. A. Goodman, A. D. Levine, J. V. Massari, H. Sugiyama, T. S. McCormick, K. D. Cooper, IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J. Immunol. 183, 3170-3176 (2009).
16. A. Schneider, S. A. Long, K. Cerosaletti, C. T. Ni, P. Samuels, M. Kita, J. H. Buckner, In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive Tregs involves IL-6-mediated signaling. Sci. Transl. Med. 5, 170ra115 (2013).
17. I. L. Campbell, T. W. Kay, L. Oxbrow, L. C. Harrison, Essential role for interferon-g and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J. Clin. Invest. 87, 739-742 (1991).
18. J. S. Rosa, R. L. Flores, S. R. Oliver, A. M. Pontello, F. P. Zaldivar, P. R. Galassetti, Sustained IL-1a, IL-4, and IL-6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus. Pediatr. Diabetes 9, 9-16 (2008).
19. Y. Dogan, S. Akarsu, B. Ustundag, E. Yilmaz, M. K. Gurgoze, Serum IL-1b, IL-2, and IL-6 in insulindependent diabetic children. Mediators Inflamm. 2006, 59206 (2006).
20. A. Wȩdrychowicz, H. Dziatkowiak, K. Sztefko, A. Wȩdrychowicz, Interleukin-6 (IL-6) and IGFIGFBP system in children and adolescents with type 1 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 112, 435-439 (2004).
21. E. M. Bradshaw, K. Raddassi, W. Elyaman, T. Orban, P. A. Gottlieb, S. C. Kent, D. A. Hafler, Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J. Immunol. 183, 4432-4439 (2009).
22. A. K. Marwaha, S. Q. Crome, C. Panagiotopoulos, K. B. Berg, H. Qin, Q. Ouyang, L. Xu, J. J. Priatel, M. K. Levings, R. Tan, Cutting edge: Increased IL-17-secreting T cells in children with newonset type 1 diabetes. J. Immunol. 185, 3814-3818 (2010).
23. A. Schneider, M. Rieck, S. Sanda, C. Pihoker, C. Greenbaum, J.H. Buckner, The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J. Immunol. 181, 7350-7355 (2008).
24. J.M. Lawson, J. Tremble, C. Dayan, H. Beyan, R.D. G. Leslie, M. Peakman, T. I. M. Tree, Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 154, 353-359 (2008).
25. R. C. Ferreira, D. F. Freitag, A. J. Cutler, J. M.M. Howson, D. B. Rainbow, D. J. Smyth, S. Kaptoge, P. Clarke, C. Boreham, R.M. Coulson, M. L. Pekalski, W.-M. Chen, S. Onengut-Gumuscu, S. S. Rich, A. S. Butterworth, A. Malarstig, J. Danesh, J. A. Todd, Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLOS Genet. 9, e1003444 (2013).
26. H. Takizawa, T. Ohtoshi, N. Yamashita, T. Oka, K. Ito, Interleukin 6-receptor expression on human bronchial epithelial cells: Regulation by IL-1 and IL-6. Am. J. Physiol 270, L346-L352 (1996).
27. N. Franchimont, C. Lambert, P. Huynen, C. Ribbens, B. Relic, A. Chariot, V. Bours, J. Piette, M.-P. Merville, M. Malaise, Interleukin-6 receptor shedding is enhanced by interleukin-1b and tumor necrosis factor a and is partially mediated by tumor necrosis factor a-converting enzyme in osteoblast-like cells. Arthritis Rheum. 52, 84-93 (2005).
28. E. M. Briso, O. Dienz, M. Rincon, Cutting edge: Soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J. Immunol. 180, 7102-7106 (2008).
29. D. W. Huang, B. T. Sherman, R. A. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
30. D. W. Huang, B. T. Sherman, R. A. Lempicki, Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1-13 (2009).
31. M. Kanehisa, S. Goto, KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 28, 27-30 (2000).
32. E. Eden, R. Navon, I. Steinfeld, D. Lipson, Z. Yakhini, GOrilla: A tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 10, 48 (2009).
33. F. Supek, M. Boşnjak, N. Şkunca, T. Şmuc, REVIGO summarizes and visualizes long lists of gene ontology terms. PLOS One 6, e21800 (2011).
34. B. Kulseng, L. Vatten, T. Espevik, Soluble tumor necrosis factor receptors in sera from patients with insulin-dependent diabetes mellitus: Relations to duration and complications of disease. Acta Diabetol. 36, 99-105 (1999).
35. J. van Dongen, R. Jansen, D. Smit, J. J. Hottenga, H. Mbarek, G. Willemsen, C. Kluft; AAGC Collaborators, B. W. Penninx, M. A. Ferreira, D. I. Boomsma, E. J. de Geus, The contribution of the functional IL6R polymorphism rs2228145, eQTLs and other genome-wide SNPs to the heritability of plasma sIL-6R levels. Behav. Genet. 44, 368-382 (2014).
36. C. Garbers, N. Monhasery, S. Aparicio-Siegmund, J. Lokau, P. Baran, M. A. Nowell, S. A. Jones, S. Rose-John, J. Scheller, The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochim. Biophys. Acta 1842, 1485-1494 (2014).
37. C. Wallace, D. J. Smyth, M. Maisuria-Armer, N.M. Walker, J. A. Todd, D. G. Clayton, The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. Nat. Genet. 42, 68-71 (2010).
38. E. Jakkula, V. Leppä, A.-M. Sulonen, T. Varilo, S. Kallio, A. Kemppinen, S. Purcell, K. Koivisto, P. Tienari, M.-L. Sumelahti, I. Elovaara, T. Pirttilä, M. Reunanen, A. Aromaa, A. B. Oturai, H. B. Søndergaard, H. F. Harbo, I.-L. Mero, S. B. Gabriel, D. B. Mirel, S. L. Hauser, L. Kappos, C. Polman, P. L. De Jager, D. A. Hafler, M. J. Daly, A. Palotie, J. Saarela, L. Peltonen, Genomewide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am. J. Hum. Genet. 86, 285-291 (2010).
39. W. W. Lin, Z. Yi, L. L. Stunz, C. J. Maine, L. A. Sherman, G. A. Bishop, The adaptor protein TRAF3 inhibits interleukin-6 receptor signaling in B cells to limit plasma cell development. Sci. Signal. 8, ra88 (2015).
40. A. Ferraro, C. Socci, A. Stabilini, A. Valle, P. Monti, L. Piemonti, R. Nano, S. Olek, P. Maffi, M. Scavini, A. Secchi, C. Staudacher, E. Bonifacio, M. Battaglia, Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 60, 2903-2913 (2011).
41. J. P. Böttcher, O. Schanz, C. Garbers, A. Zaremba, S. Hegenbarth, C. Kurts, M. Beyer, J. L. Schultze, W. Kastenmüller, S. Rose-John, P. A. Knolle, IL-6 trans-signaling-dependent rapid development of cytotoxic CD8+ T cell function. Cell Rep. 8, 1318-1327 (2014).
42. S. Bhela, C. Kempsell, M. Manohar, M. Dominguez-Villar, R. Griffin, P. Bhatt, P. Kivisakk-Webb, R. Fuhlbrigge, T. Kupper, H. Weiner, C. Baecher-Allan, Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J. Immunol. 194, 2180-2189 (2015).
43. I. Rochman, W. E. Paul, S. Z. Ben-Sasson, IL-6 increases primed cell expansion and survival. J. Immunol. 174, 4761-4767 (2005).
44. K. Hirahara, A. Onodera, A. V. Villarino, M. Bonelli, G. Sciumé, A. Laurence, H.-W. Sun, S. R. Brooks, G. Vahedi, H.-Y. Shih, G. Gutierrez-Cruz, S. Iwata, R. Suzuki, Y. Mikami, Y. Okamoto, T. Nakayama, S. M. Holland, C. A. Hunter, Y. Kanno, J. J. O'Shea, Asymmetric action of STAT transcription factors drives transcriptional outputs and cytokine specificity. Immunity 42, 877-889 (2015).
45. Y. S. Choi, D. Eto, J. A. Yang, C. Lao, S. Crotty, Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation. J. Immunol. 190, 3049-3053 (2013).
46. C. H. Kim, E. J. Kunkel, J. Boisvert, B. Johnston, J. J. Campbell, M. C. Genovese, H. B. Greenberg, E. C. Butcher, Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J. Clin. Invest. 107, 595-601 (2001).
47. P. Loetscher, M. Uguccioni, L. Bordoli, M. Baggiolini, B. Moser, C. Chizzolini, J. M. Dayer, CCR5 is characteristic of Th1 lymphocytes. Nature 391, 344-345 (1998).
48. C. Pfleger, A. Kaas, L. Hansen, B. Alizadeh, P. Hougaard, R. Holl, H. Kolb, B. O. Roep, H. B. Mortensen, N. C. Schloot; Hvidøre Study Group On Childhood Diabetes, Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes. Clin. Immunol. 128, 57-65 (2008).
49. E. A. Ivakine, O. M. Gulban, S. M. Mortin-Toth, E. Wankiewicz, C. Scott, D. Spurrell, A. Canty, J. S. Danska, Molecular genetic analysis of the Idd4 locus implicates the IFN response in type 1 diabetes susceptibility in nonobese diabetic mice. J. Immunol. 176, 2976-2990 (2006).
50. Z. Shan, B. Xu, A. Mikulowska-Mennis, S. A. Michie, CCR7 directs the recruitment of T cells into inflamed pancreatic islets of nonobese diabetic (NOD) mice. Immunol. Res. 58, 351-357 (2014).
51. R.M. McLoughlin, B. J. Jenkins, D. Grail, A. S. Williams, C. A. Fielding, C. R. Parker, M. Ernst, N. Topley, S. A. Jones, IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc. Natl. Acad. Sci. U.S.A. 102, 9589-9594 (2005).
52. T. D. Schmittgen, K. J. Livak, Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 3, 1101-1108 (2008).
53. M. D. Robinson, A. Oshlack, A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).
54. R. Development Core Team, R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, 2012).
55. D. J. McCarthy, Y. Chen, G. K. Smyth, Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 40, 4288-4297 (2012).
56. M. E. Ritchie, B. Phipson, D. Wu, Y. Hu, C. W. Law, W. Shi, G. K. Smyth, limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
57. Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. B Methodol. 57, 289-300 (1995).
58. B. Snel, G. Lehmann, P. Bork, M. A. Huynen, STRING: A web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. Nucleic Acids Res. 28, 3442-3444 (2000).
59. P. Shannon, A. Markiel, O. Ozier, N. S. Baliga, J. T. Wang, D. Ramage, N. Amin, B. Schwikowski, T. Ideker, Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504 (2003).
60. H. J. Motulsky, R. E. Brown, Detecting outliers when fitting data with nonlinear regression-A new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics 7, 123 (2006).